IDEXX Laboratories (IDXX)
(Real Time Quote from BATS)
$465.75 USD
-12.09 (-2.53%)
Updated Aug 2, 2024 10:16 AM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IDXX 465.75 -12.09(-2.53%)
Will IDXX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IDXX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IDXX
Unlocking Q2 Potential of Idexx (IDXX): Exploring Wall Street Estimates for Key Metrics
Will KORU Medical Systems Inc. (KRMD) Report Negative Earnings Next Week? What You Should Know
IDXX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
Strong CAG Sales to Aid IDEXX Laboratories' (IDXX) Q2 Earnings
TMO or IDXX: Which Is the Better Value Stock Right Now?
Other News for IDXX
IDEXX Laboratories Announces Time Change for 2024 Second Quarter Financial Results Conference Call
IDEXX Releases 2023 Corporate Responsibility Report, Highlighting Progress Against Its Goals
GLOBAL BRIEFING: Stocks seen green as US election campaign continues
Lululemon downgraded, Birkenstock upgraded: Wall Street's top analyst calls
Idexx Laboratories initiated with bullish view at BTIG, here's why